Home/Sensei Biotherapeutics/Christopher Gerry, J.D.

CG

Christopher Gerry, J.D.

President & General Counsel

Sensei Biotherapeutics

Therapeutic Areas

Sensei Biotherapeutics Pipeline

Drug	Indication	Phase
PIKTOR	Endometrial cancer, Breast cancer	Phase 1b (assumed)
Solnerstotug (SNS-101)	Advanced solid tumors	Phase 1/2

Leadership Team at Sensei Biotherapeutics

Chief Operating Officer

Josiah Craver, CPA

Bob Holmen, J.D.

View full Sensei Biotherapeutics profile